Share on LinkedInShare on LinkedIn

ARTICLE · 13 DECEMBER 2011

Intellectual Property Weekly Abstracts Bulletin - Week Of December 5, 2011

Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
Contributor
Borden Ladner Gervais LLP

Borden Ladner Gervais LLP

With over 750 lawyers, intellectual property agents and other professionals, BLG services...

View firm profile
Explore more from Borden Ladner Gervais LLP

The Court of Appeal (FCA) dismissed Merck's appeal of the Federal Court's decision to grant damages to Apotex pursuant to s. 8 of the "NOC Regulations".

CanadaIntellectual Property

Edited by Chantal Saunders and Beverley Moore

ACTIONS

Court of Appeal Dismisses Appeal in Section 8 Damages Case

Merck Frosst Canada & Co. v. Apotex Inc.
Drug: norfloxacin

The Court of Appeal (FCA) dismissed Merck's appeal of the Federal Court's decision to grant damages to Apotex pursuant to s. 8 of the NOC Regulations. Our summary of the Federal Court's decision can be found here.

The FCA considered which version of s. 8 should apply to the facts of the case and agreed with the Federal Court that Merck's application was pending when the 1998 version of the NOC Regulations came into force. Merck argued that it was an appeal, not the application before the Supreme Court. However, the FCA held that the Supreme Court had the power to give judgement in the application, thus the application was still pending. As a result, the 1998 version of s. 8 should apply.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from